OTCPK:EUCTF - Post by User
Comment by
testfreakon Sep 08, 2015 5:59pm
93 Views
Post# 24087144
RE:Potential
RE:PotentialPlay to load t.aez $.105 $45million cash
Due Diligence Provides Insight For Aeterna Zentaris Shareholders
We have two articles, published this month, that offer good insight into the Aeterna Zentaris drug pipeline and the company’s current financial position.
Our View: The cost to bring a drug to market is immense and impacts small cap companies significantly. AEZS is no exception and its cash burn is significant. With that being said, the company seems to be only months away from a significant Phase III milestone. The impact that a successful launch of ZoptEC would have on the company’s shares is mammoth and even the successful completion of a Phase III study milestone would impact the shares positively. Investors should be looking at the low price of these shares and the potential for a white knight to enter the picture.